Shares of Shire PLC (NASDAQ:SHPG) have earned an average rating of “Hold” from the nineteen research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $217.27.
A number of research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Shire from a “sell” rating to a “hold” rating in a report on Tuesday. Royal Bank of Canada set a $192.00 price target on shares of Shire and gave the stock a “buy” rating in a research report on Monday. Bank of America raised their price target on shares of Shire from $236.00 to $237.00 and gave the stock a “buy” rating in a research report on Monday. ValuEngine lowered shares of Shire from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub lowered shares of Shire from a “sell” rating to a “strong sell” rating in a research report on Friday, January 26th.
Shares of Shire (NASDAQ SHPG) traded down $2.11 during trading hours on Friday, reaching $124.12. 1,230,193 shares of the company were exchanged, compared to its average volume of 1,492,364. The company has a market capitalization of $39,350.00, a PE ratio of 23.55, a price-to-earnings-growth ratio of 0.70 and a beta of 1.41. Shire has a 1 year low of $123.73 and a 1 year high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
Several institutional investors have recently modified their holdings of the company. Harding Loevner LP grew its stake in Shire by 18,894.4% during the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after buying an additional 126,865,607 shares in the last quarter. Boston Partners boosted its holdings in Shire by 60.9% during the 4th quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock worth $363,351,000 after acquiring an additional 886,572 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Shire by 35.3% during the 3rd quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock worth $266,613,000 after acquiring an additional 454,092 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Shire by 6.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock worth $245,997,000 after acquiring an additional 96,115 shares during the last quarter. Finally, Third Point LLC purchased a new position in Shire during the 3rd quarter worth $183,768,000. Institutional investors and hedge funds own 20.31% of the company’s stock.
WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/09/shire-plc-shpg-given-average-recommendation-of-hold-by-brokerages.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.